NCT05407909View on ClinicalTrials.gov

To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

January 6, 2026

Study Completion Date

January 6, 2026

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

SYHX2001

SYHX2001 tablets, oral

Trial Locations (1)

Unknown

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY